Interim Clinical Considerations for Use of Vaccine for Monkeypox Prevention in the United States

• 2025

  Log in to bookmark this resource.

  Log in

---

Access Resources

• SummaryEN
• Ask aRCie About This Resource

About

This resource provides comprehensive information on using JYNNEOS and ACAM2000 vaccines to prevent mpox. JYNNEOS is the primary vaccine used in the ongoing clade II outbreak and is recommended for individuals at risk of orthopoxvirus exposure. Healthcare providers should assess patients’ social and sexual history to determine vaccination needs. The resource outlines the use of vaccines for pre-exposure and post-exposure prophylaxis and explains why boosters are not currently recommended for the general population. It also details the effectiveness and administration guidelines for JYNNEOS, including its use under Emergency Use Authorization.

---

Tags

Focus Area: Infectious Disease

Audiences: EMS Clinicians; Nurses; Physicians; Public Health Professionals

Emergency Management Stages: Mitigation; Response

Keywords: Antibody Formation; Immunization Schedule; Monkeypox virus; Smallpox Vaccine; Vaccination; Vaccines; Vaccines, Attenuated; Orthopoxvirus; Mpox (monkeypox); Risk Assessment; Post-Exposure Prophylaxis; Public Health Surveillance; Vaccine Efficacy

Institutions: Centers for Disease Control and Prevention (CDC)

---

More like this

Fact Sheet: United States Response to the Clade I Mpox Outbreak in Several African Countries 2024 · Centers for Disease Control and Prevention (CDC) Clade I Monkeypox Outbreak Originating in Central Africa 2025 · Centers for Disease Control and Prevention (CDC) Candida auris (C. auris) None · Centers for Disease Control and Prevention (CDC)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---